Skip to main content
. 2010 Dec 8;2010:606139. doi: 10.1155/2010/606139

Table 4.

Percentage of CD4+ T cells and CD8+ T cells producing IL-2, IL-4, IL-10, IL-13, INF-γ, and TNF-α before and after in vitro activation with phorbol 12-myristate-13-acetate and ionomycin in the four groups of asthmatics (1-intermittent, 2-mild persistent, 3-moderate persistent, and 4-severe persistent asthma). In parenthesis, the frequencies of spontaneous cytokine staining (in the presence of monensin alone) are presented.

Subgroups of asthma patients
persistent asthma
1-intermittent
n-10
2-mild
n-14
3-moderate
n-12
4-severe
n-4
CD4+/IL-2+ 7.5 ± 0.9
(3.2 ± 0.5)
7.5 ± 0.6
(2.8 ± 0.3)
9.1 ± 0.6
(2.3 ± 0.2)
6.9 ± 0.5
(3.0 ± 0.0)
CD4+/IL-4+ 9.1 ± 1.1
(3.1 ± 0.3)
9.1 ± 0.4
(3.9 ± 0.5)
9.6 ± 0.4
(3.0 ± 0.4)
7.0 ± 0.41
(3.5 ± 0.3)
CD4+/IL-10+ 7.1 ± 0.9
(5.0 ± 0.9)
8.9 ± 0.9
(3.5 ± 0.5)
8.5 ± 0.8
(3.0 ± 0.4)**
11.2 ± 0.2
(5.2 ± 0.2)
CD4+/IL-13+ 11.5 ± 0.9
(4.0 ± 0.9)
13.0 ± 0.7
(3.5 ± 0.3)
13.3 ± 0.5
(3.4 ± 0.3)
15.2 ± 0.2*
(5.2 ± 0.2)
CD4+/IFN-γ + 6.8 ± 1.3
(3.3 ± 0.5)
7.9 ± 0.7
(3.0 ± 0.3)
7.0 ± 0.5
(2.7 ± 0.2)
7.2 ± 0.2
(3.0 ± 0.0)
CD4+/TNF-α + 8.0 ± 0.9
(3.1 ± 0.3)
8.5 ± 0.5
(3.1 ± 0.2)
6.5 ± 0.6
(2.9 ± 0.1)
8.0 ± 0.4
(3.7 ± 0.0)
CD8+/IL-2+ 7.5 ± 1.0
(3.5 ± 0.5)
8.5 ± 0.8
(3.5 ± 0.4)
7.3 ± 0.7
(3.1 ± 0.2)
9.2 ± 0.2
(4.7 ± 0.2)
CD8+/IL-4+ 8.2 ± 0.9
(3.7 ± 0.5)
8.6 ± 0.4
(3.6 ± 0.3)
9.3 ± 0.4
(3.0 ± 0.2)
8.2 ± 0.2
(3.5 ± 0.2)
CD8+/IL-10+ 7.5 ± 0.8
(3.8 ± 0.5)
9.7 ± 1.0
(4.3 ± 0.6)
8.2 ± 0.6
(3.3 ± 0.4)
10.0 ± 0.0
(2.2 ± 0.2)
CD8+/IL-13+ 12.8 ± 0.9
(4.4 ± 0.6)
13.4 ± 0.7
(4.9 ± 0.7)
12.2 ± 0.5
(3.4 ± 0.3)
14.0 ± 0.5
(5.2 ± 0.7)
CD8+/IFN-γ + 7.14 ± 1.0
(3.5 ± 0.9)
8.6 ± 0.91
(3.0 ± 0.3)
7.1 ± 0.6
(2.9 ± 0.3)
6.0 ± 0.0
(3.0 ± 0.0)
CD8+/TNF-α + 7.57 ± 0.87
(3.7 ± 0.6)
9.1 ± 0.9#
(3.4 ± 0.4)
6.3 ± 0.6
(3.6 ± 0.4)
7.2 ± 0.2
(3.0 ± 0.0)

*P < .04 severe persistent asthma versus intermittent asthma.

**P < .05 severe persistent asthma versus moderate persistent asthma.

P-values from Mann-Whitney U-test.

Data as shown as mean ± SE.